MAR 9 - 2005

K050355

510(k) SUMMARY

Tissue Science Laboratories PLC, Permacol® Surgical Implant T-piece and Permacol® Surgical Implant Rectocele-piece

Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared

Victoria Taylor Tissue Science Laboratories PLC 1141 Clark Street Suite D Covington, Georgia 30014 USA

Tel: (678) 342 - 7808 Fax: (678) 342 - 7844

Email: vtaylor@tissuescience.com

Contact Person: Victoria Taylor

Date Prepared: 11th February 2005

Name of Device and Name/Address of Sponsor

Tissue Science Laboratories PLC 7th Floor, Victoria House Victoria Road Aldreshot Hampshire GU11 1 EJ United Kingdom

Trade Name

Permacol® Surgical Implant T-piece Permacol® Surgical Implant Rectocele-piece

Common or Usual Name

Surgical Mesh

Classification Name

Surgical Mesh

K050355

Predicate Devices

Permacol® Crosslinked Porcine Dermal Collagen Surgical Mesh (K992556) and Permacol® Surgical Implant (K043366)

Intended Use

Permacol® Surgical Implants are intended for use to support/reinforce soft tissue in surgical procedures. Permacol® Surgical Implant T-pieces are shaped for use in rectal intussusception repair and Permacol® Surgical Implant Rectocele-pieces are shaped for use in rectocele repair.

Technological Characteristics and Substantial Equivalence

Permacol® T-piece and Permacol® Rectocele-piece are substantially equivalent to the predicate devices because they have the same intended uses and very similar technological characteristics.

Performance Data

Biocompatibility and bench studies have been completed and support the safety and effectiveness of Permacol® Surgical Implant for its intended use, therefore data supporting the biocompatibility of Permacol® Surgical Implant T-piece and Permacol® Surgical Implant Rectocele-piece is incorporated by reference.

The biocompatibility test results show that the material used in the design and manufacture of the devices are non-toxic and non-sensitizing to biological tissues consistent with their intended use. Laboratory test results demonstrate that the materials chosen and the design utilized in manufacturing Permacol® Surgical Implant T-piece and Permacol® Surgical Implant Rectocele-piece will meet the established specification necessary for consistent performance during their intended use.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 9 - 2005

Ms. Victoria Taylor Associate Director of Regulatory Affairs Tissue Science Laboratories, PLC 1141 Clark Street, Suite D Covington, Georgia 30014

Re: K050355

Trade/Device Name: Permacol® Surgical Implant T-piece

Permacol® Surgical Implant Rectocele-piece

Regulation Number: 21 CFR 878.3300

Regulation Name: Polymeric surgical mesh

Regulatory Class: Il Product Code: FTL

Dated: February 11, 2005 Received: February 14, 2005

Dear Ms. Taylor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Miriam C. Provost, Ph.D.

Acting Director

Division of General, Restorative and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

KOT 0311

Indications for Use

510(k) Number (if	known): K0503	55		
Device Name:	Permacol® S Permacol® S	Permacol® Surgical Implant T-piece Permacol® Surgical Implant Rectocele-piece		
procedures Perma	l Implants are in	nplant T-pieces are	apport/reinforce soft tissue in surgical shaped for use in rectal intussusception es are shaped for use in rectocele repair.	
Prescription Use _ (Part 21 CFR 801		AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)	
(PLEASE DO NEEDED)	NOT WRITE B	ELOW THIS LINF	E-CONTINUE ON ANOTHER PAGE IF	
	Concurrence of	CDRH, Office of 1	Device Evaluation (ODE)	
./	2			
	isio Sign-O	•	PARE-	
		ral, Restorativ	•	
and	Newslagita	A as Sir a CES	Page 1 of	
510(k) Number	K050355		